Revolution Medicines

16 hours ago

Bookmark

Revolution Medicines is a company. It is in Redwood City, the United States and its CEO is Mark A. Goldsmith. It was founded in 2014 and is part of the Health Care sector, specifically in the Biotechnology industry.

Key facts

See more facts

Download datasets about Revolution Medicines:

Stocks from Revolution Medicines:

Exceptional Drug Discovery
Revolution Medicines is an innovative and dynamic organization of experts working together to discover and develop new medicines for cancer patients.
REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our...
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Connected or similar to Revolution Medicines: .

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.